South Korea-based SK Biopharmaceuticals has offered up to $795 million for the global rights to Biohaven’s Kv7 ion channel platform, including its lead candidate opakalim.
Biohaven has found a commercial partner for its late-stage epilepsy drug.
South Korea-based SK Biopharmaceuticals has offered up to $795 million for the global rights …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
SK Biopharm strikes $800m deal for epilepsy drug from Biohaven
SK Biopharmaceuticals to In-License Epilepsy Drug Candidate 'Opakalim'
Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal
Why Is Biohaven Stock Soaring Wednesday? - Biohaven (NYSE:BHVN)
Teva saddles up as stalking horse bidder for bankrupt BioXcel’s neuroscience portfolio
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and…
SK Biopharmaceuticals is staking nearly $800 million on rights to an epilepsy treatment from US biotech firm Biohaven, the…
SK Biopharmaceuticals to In-License Epilepsy Drug Candidate 'Opakalim'
Faced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental…
Biohaven gains $795M in global licensing deal and $4M lawsuit win. BHVN jumps 13% as William Blair eyes upcoming trial data.
Biohaven (BHVN) shares fall as BofA downgrades the stock to Underperform, citing a risky profile ahead of key epilepsy trial data.
